Search

Your search keyword '"Lahoz C"' showing total 856 results
Start Over Author "Lahoz C"
856 results on '"Lahoz C"'

5. SEA 2022 standards for the comprehensive control of cardiovascular risk

Author

Mostaza, J.M., Pintó, X., Armario, P., Masana, L., Real, J.T., Valdivielso, P., Arrobas-Velilla, T., Baeza-Trinidad, R., Calmarza, P., Cebollada, J., Civera-Andrés, M., Cuende Melero, J.I., Díaz-Díaz, J.L., Fernández Pardo, J., Guijarro, C., Jericó, C., Laclaustra, M., Lahoz, C., López-Miranda, J., Martínez-Hervás, S., Muñiz-Grijalvo, O., Páramo, J.A., Pascual, V., Pedro-Botet, J., Pérez-Martínez, P., Plana, N., Puzo, J., Sánchez Chaparro, M.Á., and Vila, L.

Published
2022
Full Text
View/download PDF

6. Estándares SEA 2022 para el control global del riesgo cardiovascular

Author

Mostaza, Jose Maria, Pintó, Xavier, Armario, Pedro, Masana, Luis, Real, José T., Valdivielso, Pedro, Arrobas-Velilla, Teresa, Baeza-Trinidad, Ramón, Calmarza, Pilar, Cebollada, Jesús, Civera-Andrés, M., Cuende Melero, J.I., Díaz-Díaz, J.L., Fernández Pardo, J., Guijarro, C., Jericó, C., Laclaustra, M., Lahoz, C., López-Miranda, J., Martínez-Hervás, S., Muñiz-Grijalvo, O., Páramo, J.A., Pascual, V., Pedro-Botet, J., Pérez-Martínez, P., Plana, N., Puzo, J., Sánchez Chaparro, M.Á., and Vila, L.

Published
2022
Full Text
View/download PDF

10. Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society

Author

Suárez Tembra, M., Iglesias, Gonzalo Pías, Carbayo Herencia, J.A., Guerrero Buitrago, C., Vila, L., Morales Coca, C., Llargués Rocabruna, E., Perea Castillo, V., Pedro-Botet, J., Climent, E., Mauri Pont, M., Pinto, X., Ortega Martínez de la Victoria, E., Amor, J., Zambón Rados, D., Blanco Vaca, F., Ramiro Lozano, J.M., Fuentes Jiménez, F.J., Soler, I., Ferrer, C., Zamora Cervantes, A., Vila Belmonte, A., Novoa Mogollón, F.J., Sanchez-Hernández, R.M., Expósito Montesdeoca, A.B., Romero Jiménez, M.J., González García, M.P., Bueno Díez, M., Brea Hernando, A., Lahoz, C., Mostaza Prieto, J., Millán Núñez-Cortés, J., Reinares García, L., Blanco Echevarría, A., Ariza Corbo, María José, Rioja Villodres, J., Sánchez-Chaparro, M.A., Jansen Chaparro, S., Sáenz Aranzubía, P., Martorell Mateu, E., Almagro Múgica, F., Muñiz Grijalvo, O., Masana Martín, L., Plana Gil, N., Ibarretxe Gerediaga, D., Rodríguez Borjabad, C., Zabala López, S., Hernández Mijares, A., Ascaso Gimilio, J.F., Pérez García, L., Civeira Murillo, F., Pérez-Calahorra, S., Lamiquiz-Moneo, I., Mateo Gallego, R., Marco Benedí, V., Ferrando Vela, J., Ariza, María José, Rioja, José, Ibarretxe, Daiana, Camacho, Ana, Díaz-Díaz, José Luis, Mangas, Alipio, Carbayo-Herencia, Julio A., Ruiz-Ocaña, Pablo, Lamíquiz-Moneo, Itziar, Mosquera, Daniel, Sáenz, Pedro, Masana, Luis, Muñiz-Grijalvo, Ovidio, Pérez-Calahorra, Sofía, and Valdivielso, Pedro

Published
2018
Full Text
View/download PDF

17. Self-configuring programmable silicon photonic filter for integrated microwave photonic processors.

Author

Catalá-Lahoz, C., Pérez-López, D., Huy-Ho, T., and Capmany, J.

Subjects
MICROWAVE filters, INFINITE impulse response filters, MICROWAVE communication systems, RESONATOR filters, SIGNAL processing, RADIO frequency
Abstract

Reconfigurable photonic filters show great promise as a potential solution to meet the evolving needs of future microwave communication systems. By integrating high-performance filters into programmable microwave photonic processors, they can provide significant benefits for signal processing applications. The development of an algorithm that can automatically characterize and reconfigure the filter using a single optical input and output port is essential for this purpose. This paper presents an optimization technique for a fully tunable ring-assisted Mach–Zehnder interferometer filter. The proposed filter design eliminates the need for monitoring components and employs a novel algorithm that operates independently in each ring by switching between the two arms of the filter. In addition, the filter can be configured to implement different filter architectures, allowing for flexible filtering requirements. Measurements were performed using the device as an interleaver, implementing different types of infinite impulse response filters in the optical and radio frequency domains. Side-coupled integrated spaced sequence of resonator filters were also implemented by reconfiguring the same device. These results demonstrate the exceptional reconfigurability of the filter design proposed herein in terms of bandwidth and central frequency. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. SEA 2022 Standards for Global Control of Cardiovascular Risk

Author

Universitat Rovira i Virgili, Mostaza JM; Pintó X; Armario P; Masana L; Real JT; Valdivielso P; Arrobas-Velilla T; Baeza-Trinidad R; Calmarza P; Cebollada J; Civera-Andrés M; Cuende Melero JI; Díaz-Díaz JL; Fernández Pardo J; Guijarro C; Jericó C; Laclaustra M; Lahoz C; López-Miranda J; Martínez-Hervás S; Muñiz-Grijalvo O; Páramo JA; Pascual V; Pedro-Botet J; Pérez-Martínez P; Plana N; Puzo J; Sánchez Chaparro M; Vila L, Universitat Rovira i Virgili, and Mostaza JM; Pintó X; Armario P; Masana L; Real JT; Valdivielso P; Arrobas-Velilla T; Baeza-Trinidad R; Calmarza P; Cebollada J; Civera-Andrés M; Cuende Melero JI; Díaz-Díaz JL; Fernández Pardo J; Guijarro C; Jericó C; Laclaustra M; Lahoz C; López-Miranda J; Martínez-Hervás S; Muñiz-Grijalvo O; Páramo JA; Pascual V; Pedro-Botet J; Pérez-Martínez P; Plana N; Puzo J; Sánchez Chaparro M; Vila L

Abstract

One of the objectives of the Spanish Society of Arteriosclerosis is to contribute to better knowledge of vascular disease, its prevention and treatment. It is well known that cardiovascular diseases are the leading cause of death in our country and entail a high degree of disability and health care costs. Arteriosclerosis is a multifactorial disease and therefore its prevention requires a global approach that takes into account the different risk factors with which it is associated. Therefore, this document summarizes the current level of knowledge and includes recommendations and procedures to be followed in patients with established cardiovascular disease or at high vascular risk. Specifically, this document reviews the main symptoms and signs to be evaluated during the clinical visit, the laboratory and imaging procedures to be routinely requested or requested for those in special situations. It also includes vascular risk estimation, the diagnostic criteria of the different entities that are cardiovascular risk factors, and makes general and specific recommendations for the treatment of the different cardiovascular risk factors and their final objectives. Finally, the document includes aspects that are not usually referenced in the literature, such as the organization of a vascular risk consultation.

Published
2022

31. Statement of the Spanish interdisciplinary vascular prevention committee on the updated European guidelines on cardiovascular disease prevention 2021 Comentario del CEIPV a las nuevas guías europeas de prevención cardiovascular 2021

Author

Brotons, Carlos, Camafort, M., Castellanos, M.d.M., Clarà, A., Cortés, O., Díaz Rodríguez, Á., Elosua, R., Gorostidi, M., Hernández, A.M., Herranz, M., Justo, S., Lahoz, C., Niño, P., Pallarés-Carratalá, V., Pedro-Botet, J., Pérez Pérez, Antonio, Royo-Bordonada, M.Á., Santamaría, R., Tresserras, R., Zamora, A., Zuza, I., and Armario, P.

Subjects
Prevention and control, Arterial hypertension, Healthy diet, Lipid control, Diabetes, Smoking, Clinical practice guidelines, Cardiovascular risk, Vascular diseases
Abstract

We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease (CVD) prevention in clinical practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-Cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (Step 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After Step 1, considering proceeding to the intensified goals of Step 2 is mandatory, and this intensification will be based on 10-year CVD risk, lifetime CVD risk and treatment benefit, comorbidities and patient preferences. The updated SCORE algorithm (SCORE2 and SCORE-OP) is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal CVD events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according different age groups (< 50, 50-69, ≥ 70 years). Different flow charts of CVD risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic CVD, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.

Published
2022

33. SEA 2022 Standards for Global Control of Cardiovascular Risk

Author

Mostaza, Jose Maria, Pintó, Xavier, Armario, Pedro, Masana, Luis, Real, José T, Valdivielso, Pedro, Arrobas-Velilla, Teresa, Baeza-Trinidad, Ramón, Calmarza, Pilar, Cebollada, Jesús, Civera-Andrés, M, Cuende Melero, J I, Díaz-Díaz, J L, Fernández Pardo, J, Guijarro, C, Jericó, C, Laclaustra, M, Lahoz, C, López-Miranda, J, Martínez-Hervás, S, Muñiz-Grijalvo, O, Páramo, J A, Pascual, V, Pedro-Botet, J, Pérez-Martínez, P, Plana, N, Puzo, J, Sánchez Chaparro, M Á, and Vila, L

Subjects
Arterial hypertension, Dyslipidaemia, Arteriosclerosis, Diabetes, Smoking, Tabaquismo, Fibrilación auricular, Hipertensión arterial, Cardiovascular prevention, Dislipemia, Cardiovascular Diseases, Heart Disease Risk Factors, Risk Factors, Atrial Fibrillation, Prevención cardiovascular, Humans
Abstract

One of the objectives of the Spanish Society of Arteriosclerosis is to contribute to better knowledge of vascular disease, its prevention and treatment. It is well known that cardiovascular diseases are the leading cause of death in our country and entail a high degree of disability and health care costs. Arteriosclerosis is a multifactorial disease and therefore its prevention requires a global approach that takes into account the different risk factors with which it is associated. Therefore, this document summarizes the current level of knowledge and includes recommendations and procedures to be followed in patients with established cardiovascular disease or at high vascular risk. Specifically, this document reviews the main symptoms and signs to be evaluated during the clinical visit, the laboratory and imaging procedures to be routinely requested or requested for those in special situations. It also includes vascular risk estimation, the diagnostic criteria of the different entities that are cardiovascular risk factors, and makes general and specific recommendations for the treatment of the different cardiovascular risk factors and their final objectives. Finally, the document includes aspects that are not usually referenced in the literature, such as the organization of a vascular risk consultation. Copyright © 2021 The Authors. Publicado por Elsevier Espana, S.L.U. All rights reserved.

Published
2021

34. Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry

Author

Balaz D., Wikman-Jorgensen P.E., Galvañ V.G., Rubio-Rivas M., Campo B.M., López M.N., Caleya J.F.L., Huelgas R.G., Fontán P.M.P., Bailón M.M., Fernández-Garcés M., Cruz A.F., García García G.M., Rhyman N., Corral-Gudino L., Rodríguez-Mancheño A.L., De La Chica M.N., García A.T., Alcalá J.N., Jiménez P.D., Royo Trallero L.E., Casanova P.C., Núñez-Cortés J.M., Casas-Rojo J.-M., Corbella X., Homs N., Montero A., Mora-Luján J.M., De Blas P.A., Cañas C.A., Ayuso B., Morejón J.B., Escudero S.C., Frías M.C., Tejido S.C., Pedroche C.D., Simon R.D., Reyne A.G., Veganzones L.I., Huerta L.J., Blanco A.L., Gonzalo J.L., Lora-Tamayo J., Bermejo C.L., De La Calle G.M., Godoy R.M., Perpiña B.O., Ruiz D.P., Fernández M.S., Montes J.T., Bandera V.A., Alegría J.G., Jiménez-García N., Del Pino J.L., Escalante M.D.M., Romero F.N., Rodriguez V.N., Sierra J.O., Casas L.A., De Oña Á.A., Beato R.A., Gonzalo L.A., Muñoz J.A., Amodeo Oblitas C.M., García C.A., Cebrián M.B., Corral J.B., Guerrero M.B., Estrada A.D.B., Moreno M.C., Fernández P.C., Carrillo R., Pérez S.C., Muñoz E.C., Moreno A.D.C., Carvajal M.C.C., De Santos S., Gómez A.E., Carracedo E.F., Jenaro M.M.F.-M., Galeano Valle F., Garcia A., Fernandez-Bravo I.G., Leoni M.E.G., Antúnez M.G., Narciso C.G.S., Gurjian A.A., Ibáñez L.J., Olleros C.L., Mendo C.L., García S.L., Jimeno V.M., Nohales C.M., Ledesma S.M., Míguez A.M., Delgado C.M., Ortega L.O., Sánchez S.P., Virto A.P., Sanz M.T.P., Llorente B.P., Ruiz S.P., Fernández-Llamazares G.S., Macías M.T., Samaniego N.T., Do Rego A.T., Garcia M.V.V., Villarreal G., Etayo M.Z., Suárez A.M.Á., Vergés C.D., Martínez R.F.-M., Aizpuru E.M.F., Carrasco A.G., Amezua C.H., Martínez D.L., López M.M.M., Zapico A.M., Iscar C.O., Casado L.P., Martínez M.L.T., Chamorro L.M.T., Ayala-Gutiérrez M.M., López R.B., Fonseca J.B., Buonaiuto V.A., Martínez L.F.C., Palacios L.C., Muriel C.C., De Windt F., Christophel A.T.F.-T., Ocaña P.G., García J.G., Hurtado Oliver J.A., Jansen-Chaparro S., López-Carmona M.D., Quirantes P.L., Sampalo A.L., Lorenzo-Hernández E., Sevilla J.J.M., Carmona J.M., Pérez-Belmonte L.M., De Pedro I.P., Pineda-Cantero A., Gómez C.R., Ricci M., Cánovas J.S., Troncoso J.Á., Fernández F.A., Quintana F.B., Arenzana C.B., Molina S.C., Candalija A.C., Bengoa G.D., Grela A.G., Hernández A.L., Vidal A.D., Capitán C.F., Iglesias M.F.G., Muñoz B.G., Gil C.R.H., Martínez J.M.H., Hontañón V., Hernández M.J.J., Lahoz C., Calvo C.M., Gutiérrez J.C.M., Prieto M.M., Robles E.M., Saldaña A.M., Fernández A.M., Prieto J.M.M., Mozo A.N., López C.M.O., Peláez E.P., Pampyn M.P., Simón M.A.Q., Ramos J.C., Ruperto L.R., Purificación A.S., Bueso T.S., Torre R.S., Abanedes C.I.S., Tabares Y.U., Mayoral M.V., Manau J.V., Rivera N.A., Vieitez A.C., Beamonte E.D.C., Manglano J.D., Mera I.F., Andreu M.D.M.G., Aseguinolaza M.G., Lezaun C.G., Laorden C.J., Murgui R.M., Sanz M.T.M., Abad M.D.C.B., Romero M.A.F., Castro S.M., Guillan E.M.P., Nuñez M.P., Fontan P.M.P., Yeguas I.A., Gómez J.A., Cuchillo J.B., López I.B., Clotet N.C., Elías A.E.C., Manuel E.C., De Luque C.M.C., Benbunan C.C., Vilan L.D., Hernández C.D., Peralta E.E.D., Pérez V.E., Fernandez-Castelao S., Saavedra M.O.F., Klepzig J.L.G., and Bermúdez M.

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Medicina, Enfermedades infecciosas, comorbidities, Article, corticosteroids, Who recommendations, Prednisone, Internal medicine, D-dimer, medicine, Oxygen saturation (medicine), business.industry, Adrenocortical hormones, COVID-19, General Medicine, Corticosteroides, medicine.disease, Obesity, Comorbidity, nervous system diseases, Spain, Medicine, National registry, business, medicine.drug
Abstract

Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years, p &lt, 0.001), with hypertension (57.0% vs. 47.7%, 0.001), obesity (26.4% vs. 19.3%, 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%, 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7–160) vs. 49.3 (16–109) mg/dL, 0.001), ferritin (791 (393–1534) vs. 470 (236–996) µg/dL, 0.001), D dimer (750 (430–1400) vs. 617 (345–1180) µg/dL, 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101), 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September, 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation &lt, /=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation &lt, /=90%.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results